Enrollment closed to new patients in the Phase I trial investigating lirilumab in combination with ipilimumab

• Lirilumab clinical development ongoing, including Phase II monotherapy trial in AML and three Phase I combination trials with nivolumab and elotuzumab

• Clinical program for lirilumab broadened with two new trials opened in October 2014

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today that Bristol-Myers Squibb has closed new patient enrollment in the Phase I trial testing the combination of lirilumab and ipilimumab in selected solid tumors (CA223-002). There were no safety issues leading to this decision and patients still under treatment or in active follow-up will continue as planned in the study protocol.

Hervé Brailly, CEO and co-founder of Innate Pharma, said: “We look forward to seeing data from the ongoing lirilumab trials including the combination of nivolumab and lirilumab in solid tumors, which is nearly fully accrued as well as from the monotherapy efficacy trial in AML which completed recruitment in July 2014”.

The clinical development program of lirilumab was recently expanded with two new combination trials started in October.